Gilead Seeks Approval for Hepatitis C Treatment for All Genotypes

Article

The FDA is reviewing Gilead Sciences' new drug application (NDA) for a fixed dose combination of sofosbuvir (Solvadi) and velpatasvir to treat genotype 1-6 hepatitis C virus infection.

The FDA is reviewing Gilead Sciences’ new drug application (NDA) for a fixed dose combination of sofosbuvir (Solvadi) and velpatasvir to treat genotype 1-6 hepatitis C virus infection.

If the FDA approves the drug, the once-daily combination would be the first all-oral, pan-genotypic single tablet for the chronic infection.

The NDA includes data from clinical studies that examined the use of sofosbuvir (SOF) and velpatasvir (VEL) for 12 weeks in patients with genotype 1-6 hepatitis C infection, including those with compensated cirrhosis.

The NDA also includes information about 12 weeks of the SOF/VEL treatment with ribavirin for patients with decompensated cirrhosis.

"As the first fixed-dose combination of 2 pan-genotypic, direct-acting antivirals, SOF/VEL represents an important step forward in the treatment of patients with hepatitis C,” said Norbert

Bischofberger, executive vice president of research and development and chief scientific officer at Gilead. “SOF/VEL complements our current HCV portfolio of Sovaldi and Harvoni, offering high cure rates and the potential to simplify treatment and eliminate the need for HCV genotype testing.”

The FDA has granted breakthrough therapy designation to Gilead for the combination treatment.

Thus far, adverse effects associated with the sofosbuvir and velpatasvir treatment have been headache, fatigue, and nausea.

Related Videos
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.